NCF2 Gene Chronic Granulomatous Disease Type 2 (Cytochrome b‑Positive) DNA Test in UAE

Executive Summary & Core Metrics

Executive Summary: Delivering 99.9% analytical sensitivity and specificity for NCF2 variant detection through ISO‑accredited next‑generation sequencing. VIP mobile phlebotomy with temperature‑controlled cold‑chain logistics available daily from 8 AM to 11 PM. Post‑test tele‑genetic counseling provided for result interpretation and family risk assessment. Direct insurance billing verification via WhatsApp at +971 54 548 8731. Turnaround time of 3 to 4 weeks from sample receipt.

Test Overview & Methodology

This NGS‑based genetic test identifies pathogenic variants in the NCF2 gene responsible for autosomal recessive chronic granulomatous disease type 2 (cytochrome b‑positive), enabling definitive diagnosis, carrier detection, and family cascade screening. Full exon coverage with splice site analysis and CNV detection ensures comprehensive molecular characterization.

Feature	Our Test (NGS Genetic Analysis)	Closest Alternative (DHR Flow Cytometry)
Precision	99.9% analytical sensitivity & specificity for variant detection	Functional – cannot distinguish carrier status or specific gene
Methodology	NGS with full exon coverage, splice site analysis, CNV detection + Sanger confirmation	Neutrophil oxidative burst (DHR) flow cytometry
Turnaround Time	3 to 4 weeks	1 to 2 days (functional assay only, does not replace genetic diagnosis)

Physician Insight & Safety Protocols

“A molecular diagnosis of CGD type 2 through NCF2 gene sequencing provides the definitive etiologic answer that functional assays alone cannot deliver. For families navigating recurrent infections and granulomatous complications, early genetic confirmation guides targeted prophylactic therapy, informs reproductive planning, and enables precise carrier testing among at‑risk relatives. Correlation with the full clinical phenotype remains essential.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403

Pre‑Test Genetic Counseling & Preparation

A mandatory genetic counseling session is conducted to document a three‑generation family pedigree and assess recurrence risk.
Comprehensive clinical history of recurrent infections, granulomatous lesions, and affected relatives must be provided prior to testing.
Sample options include whole blood, extracted DNA, or a single dried blood spot on an FTA card collected by a certified phlebotomist.

Exclusion Criteria & Emergency Red Flags

This genetic test is not indicated for acute infection management; it is a molecular diagnostic tool, not a rapid assay.
Minors require written guardian consent in accordance with UAE Personal Data Protection Law (PDPL).
Seek emergency care immediately if the patient experiences high fever, difficulty breathing, rapidly spreading skin abscesses, or severe bone pain, as these may indicate a life‑threatening infection independent of test results.

Patient FAQ & Clinical Guidance

1. What is the purpose of the NCF2 Gene CGD Type 2 DNA Test?

This NGS‑based genetic test detects disease‑causing variants in the NCF2 gene to confirm autosomal recessive chronic granulomatous disease type 2 and identify carrier status in at‑risk family members. It provides a definitive molecular diagnosis that guides clinical management and reproductive decision‑making.

2. How is the sample collected, and when will I receive my results?

A certified phlebotomist performs a home blood draw under temperature‑controlled cold‑chain logistics, or you may provide an FTA card sample. Genetic results are delivered within 3 to 4 weeks from sample receipt, with a detailed clinical interpretation report.

3. Is this genetic test covered by UAE health insurance?

We offer direct billing verification with all major UAE insurers. WhatsApp your policy details to +971 54 548 8731 for instant coverage confirmation and pre‑authorization assistance.

4. What does a positive test result mean for my family members?

A positive result confirms autosomal recessive CGD type 2, meaning each sibling has a 25% chance of being affected and a 50% chance of being a carrier. Post‑test genetic counseling is provided to discuss cascade testing, reproductive options, and preventive care strategies for family members.

UAE Regulatory & Data Privacy Adherence

Data Privacy & Health Information Governance: DNA Labs UAE operates in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, access‑controlled, and processed under strict confidentiality protocols. Clinical safety and patient consent are governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability. Your genetic information is used solely for diagnostic purposes and is never shared without explicit written consent.

Clinical & Logistical Metadata

Test Name	NCF2 Gene Chronic Granulomatous Disease Type 2 (Cytochrome b‑Positive) DNA Test
Price (AED)	2,800 AED
Turnaround Time	3 to 4 weeks
Sample Type / Matrix	Whole Blood, Extracted DNA, or FTA Card Sample
Methodology Used	Next‑Generation Sequencing (NGS) with Full Exon Coverage, Splice Site Analysis, CNV Detection + Sanger Confirmation
ICD‑10‑CM Code	D71
LOINC Code	94468-1
DHA Facility License & Laboratory Address	Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| License No: 1143 \| DNA Labs UAE